Kinaxis Launches 2023 Global Impact Report, Furthering the Company’s Focus on People, Planet and Supply Chain Progress
Kinaxis ® Inc. (TSX:KXS), the leading provider of supply chain management solutions, today published its 2023 Global Impact Report. The report highlights the company’s achievements across its core Environmental, Social and Corporate Governance (ESG) commitments, as well as its focus on preserving the planet, supporting its employees and advancing the broader supply chain industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230901526687/en/
Highlights from the report include:
- Achieving Triple A designation from MSCI and top marks from several other rating agencies
- Purchasing Renewable Energy Certificates (RECs) to account for all Head Office electricity use in 2022
- Maintaining our carbon neutral certification since 2019
- Growing women in leadership (director level and above) to 26% in 2022
- Obtaining a high employee belonging rating (96% feel as though they are an accepted member of their team)
- Supporting more than 40 emerging artists through free studio time and public performances through our Catapult collaboration
In addition, this year Kinaxis announced its Sustainable Supply Chain solution, which allows companies to track Scope 3 greenhouse gas emissions and understand how changes to their supply chain plans can positively or negatively impact those emissions.
“I am proud of our progress in this year’s Global Impact Report and take tremendous pride in our company’s strong commitment to ESG and preserving the planet,” said John Sicard, president and CEO of Kinaxis. “There is no larger consumer of the earth’s natural resources than supply chain, so it is our responsibility to continue to advance our personal commitments as well as those of our customers by innovating in ways that help them meet their corporate goals, while doing less harm. I am confident that our new Sustainable Supply Chain solution will do just that.”
More details on all the ESG commitments and initiatives made by Kinaxis can be found in its 2023 Global Impact Report.
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
Everyday volatility and uncertainty demand quick action. Kinaxis® delivers the agility to make fast, confident decisions across integrated business planning and the digital supply chain. People can plan better, live better and change the world. Trusted by innovative brands, we combine human intelligence with AI and concurrent planning to help companies plan for any future, monitor risks and opportunities and respond at the pace of change. Powered by an extensible, cloud-based platform, Kinaxis delivers industry-proven applications so everyone can know sooner, act faster and remove waste. For more Kinaxis news, visit Kinaxis.com or follow us on LinkedIn, Twitter, Facebook.
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to Kinaxis' growth opportunities and the potential benefits of, and demand for, Kinaxis’ products and services. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of Kinaxis' products and services compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. Kinaxis' actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of Kinaxis to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by Kinaxis with Canadian securities regulatory authorities. Kinaxis assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Jaime Cook | Kinaxis
Rick Wadsworth | Kinaxis
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Provides Update on EXKIVITY® (mobocertinib)2.10.2023 23:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY ® (mobocertinib) in the U.S. for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-based chemotherapy. Takeda intends to similarly initiate voluntary withdrawal globally where EXKIVITY is approved and is working with regulators in other countries where it is currently available on next steps. This decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint and thus did not fulfill the confirmatory data requirements of the Accelerated Approval granted by the U.S. FDA nor the conditional marketing approvals granted in other countries. The EXCLAIM-2 trial was a Phase
Galderma announces progress with RelabotulinumtoxinA regulatory submissions2.10.2023 23:27:00 EEST | Press release
Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”). The FDA has issued a Complete Response Letter (“CRL”) to Galderma related to its BLA for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adult patients as well as moderate-to-severe lateral canthal lines (crow’s feet) associated with orbicularis oculi muscle activity in adult patients. The CRL points out certain deficiencies isolated to items related to Chemistry, Manufacturing, and Controls (“CMC”) processes. All other aspects of the BLA, including safety and efficacy related parts, did not solicit deficiencies to be addressed. Galderma has already identified changes to the manufacturing process to address feedback. It will also
Visa Launches $100 million Generative AI Ventures Initiative2.10.2023 23:05:00 EEST | Press release
Visa (NYSE: V), a global leader in payments, today announced a new $100 million generative AI ventures initiative to invest in the next generation of companies focused on developing generative AI technologies and applications that will impact the future of commerce and payments. As a pioneer of AI use in payments since 1993, Visa considers this initiative an extension of Visa’s leadership in using AI to drive innovation in payments, create value for partners and clients, and enable and empower global commerce. Generative AI is an emerging subset of AI that is built on Large Language Models (LLMs) to develop artificial general intelligence capable of generating text, images or other content from large sets of existing data when given prompts. “While much of generative AI so far has been focused on tasks and content creation, this technology will soon not only reshape how we live and work, but it will also meaningfully change commerce in ways we need to understand,” said Jack Forestell,
MSCI Completes Acquisition of Burgiss2.10.2023 23:05:00 EEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that it has completed its acquisition of The Burgiss Group, LLC (“Burgiss”), a market-leading provider of data, analytics, and technology solutions for investors in private assets. The acquisition was originally announced on August 14, 2023. Henry Fernandez, Chairman and Chief Executive Officer, MSCI, said: “We are thrilled to complete this acquisition. By making Burgiss part of our integrated franchise, MSCI will dramatically expand and strengthen our solutions across client segments. In the process, we will help promote greater transparency for investors in private assets." About MSCI Inc. MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand
Carbios Unveils Major Innovation in Polyester Recycling With New Textile Preparation Line, in the Presence of Roland Lescure, French Minister of Industry2.10.2023 19:00:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231002227008/en/ Roland Lescure, French Minister of Industry (left) accompanied by Emmanuel Ladent, CEO Carbios (far right) and representatives of Carbios partner brands (On, Salomon and Puma), inaugurates the textile preparation line for biorecycling. (Photo: Carbios) Carbios, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, today inaugurated its textile preparation line at its demonstration plant in Clermont-Ferrand, in the presence of Mr. Lescure, French Minister for Industry. To streamline the textile preparation phase, which is currently carried out by hand or on several lines, Carbios has developed a fully integrated and automated line that transforms textile waste from used garments or cutting scraps into raw material suitable for depolymerizat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom